Claudin 18.2在恶性实体肿瘤中的研究现状与展望  

Research progress and prospect of Claudin 18.2 in malignant tumors

作　　者：范密 罗婷[2] 张羽[3] 杜小波 FAN Mi;LUO Ting;ZHANG Yu;DU Xiaobo(Department of Clinical Medicine,North Sichuan Medical College,Nanchong,Sichuan 637000,P.R.China;Breast Disease Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Department of Oncology,Mianyang Central Hospital,Mianyang,Sichuan 621000,P.R.China)

机构地区：[1]川北医学院临床医学系,四川南充637000 [2]四川大学华西医院乳腺疾病中心,成都610041 [3]绵阳市中心医院肿瘤科,四川绵阳621000

出　　处：《华西医学》2023年第9期1428-1434,共7页West China Medical Journal

基　　金：国家卫生健康委员会核技术医学转化重点实验室开放课题(2022HYX001)。

摘　　要：在恶性实体瘤转化的过程中,紧密连接蛋白Claudins的表达常常是失调的。Claudins几乎涵盖了肿瘤生物学的每个方面以及癌症进展的所有阶段,这表明它们有望成为恶性实体瘤诊断、预后的生物标志物以及治疗的新靶点。目前研究发现Claudin18.2在胃癌、胰腺癌、卵巢癌等疾病中过度表达,基于Claudin 18.2为靶点的抗肿瘤靶向治疗已成为近年来的研究热点。因此,该文综述了Claudin18.2的基本结构特征、在各种恶性实体瘤中的表达情况及研究应用成果进展以及展望。In the process of solid tumor transformation,the expression of claudins is often dysregulated.Claudins are involved in almost all aspects of tumor biology and steps of tumor development,suggesting that they have the potential to be diagnostics,and prognostic biomarkers and therapeutic targets.Current studies have found that Claudin18.2 is overexpressed in gastric cancer,pancreatic cancer,ovarian cancer and other diseases.Targeted anti-tumor therapy based on Claudin 18.2 has become a research hotspot recently.Therefore,this article reviews the basic structural characteristics of Claudin18.2,its expression in various malignant solid tumors,the progress of research and application,and prospect.

关 键 词：Claudin 18.2 肿瘤 靶向治疗 

分 类 号：R730[医药卫生—肿瘤]